BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.81 -0.39%

-$0.03 today

Market cap
$144.85M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.58M

Average 0.37M

BBOT Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow grows to $295K

Q1 FY2026 financing cash flow was $295K, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $402.65M.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near $295K or moves back toward the trailing-twelve-month quarterly average of $100.66M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$295K+150.3% QoQ
Last fiscal yearDec 2025
$383.4M+105.6% YoY
LTMMar 2026
$402.65M+1936.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+105.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
383.4M USD
Year-over-year change
+105.6%

Financing Cash Flow vs competitors

How BBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1936.0% is the 3rd highest of 10, against a peer median of -32.9%.
BBOT Competitors
Financing Cash Flow for BBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNGXTango Therapeutics, Inc.LTM Sep 2026$974.19M USD+23701.4%+416.5%—
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$402.65M USD+1936.0%——
NRIXNurix Therapeutics, Inc.LTM Aug 2026$261.21M USD+28.6%+26.8%37.2%
KODKodiak Sciences Inc.LTM Sep 2026$187.21M USD+12713.7%+354.8%—
OCSOculis Holding AGLTM Mar 2026CHF 105.86M CHF-32.9%+370.6%21003.4%
URGNUroGen Pharma Ltd.LTM Mar 2026$105.09M USD-24.9%-25.7%74.8%
ANABAnaptysBio, Inc.LTM Mar 2026$102.81M USD-191.7%—44.2%
SEPNSepterna, Inc.LTM Sep 2026$80.93M USD-73.5%-61.7%84.1%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$66.35M USD-61.6%—32.4%
XNCRXencor, Inc.LTM Jun 2026$8.3M USD-95.9%+13.0%7.9%
Peer median (excluding BBOT) —-32.9%+26.8%44.2%

Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(74)(3.52K)(41.69K)7.6M(134.04M)
Depreciation & Amortization0000610K
Deferred Income Tax00000
Stock-Based Compensation000271.57K5.87M
Change in Working Capital0015K(104.61K)6.43M
Accounts Receivables00000
Inventory00000
Accounts Payables000172.52K(1.84M)
Other Working Capital0015K(277.13K)8.27M
Other Non-Cash Items743.52K26.69K(8.53M)7.23M
Operating Cash Flow00(52.08M)(763.82K)(113.89M)
Capital Expenditures0000(606K)
Acquisitions (Net)00000
Purchases of Investments000(184M)(83.93M)
Sales of Investments0000157.86M
Other Investing Activities00000
Investing Cash Flow000(184M)73.33M
Debt Repayment000(209.85K)0
Common Stock Issued000187.25M395.72M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities000(578.55K)(12.32M)
Financing Cash Flow000186.46M383.4M
Effect of Forex Changes00000
Net Change in Cash00225K1.7M342.84M
Free Cash Flow00(52.49M)(763.82K)(114.5M)

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Intrinsic Alpha fair value

Locked

Current Price

$1.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.